News and Announcements
Imugene Annual Update 2016; Clinical Sites in Asia Opened & New Substantial Shareholder
- Published January 18, 2017 5:24PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Ltd (ASX: IMU) is an immuno-oncology focused biopharmaceutical company, developing HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. In no order of importance are listed Imugene’s achievements of 2016;
- A successful capital raising, in doing so bringing on a substantial shareholder in The Platinum Asset Management Fund.
- Opened our clinical sites in Asia and we look forward to enrolling the first cohort of patients.
- Progressed our mimotope discovery platform with the filing of four important patents.
Imugene are proud to have maintained and strengthened their already strong international intellectual property position. Also mentioning the progress made by their scientific team, both at home and abroad in Vienna.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
